Christopher Klebanoff was Honored with G-Rex Grant for TCR-T cell Therapy Program

Christopher Klebanoff is an Associate Member and Attending Physician at Memorial Sloan Kettering Cancer Center. He is a scientific co-founder of Affini-T Therapeutics and serves as an investigator at the Parker Institute for Cancer Immunotherapy.

His research specifically targets the enhancement of cancer immunotherapy and the detailed mechanisms of immune responses in cancer treatment.an Associate Member at Memorial Sloan Kettering Cancer Center, has been honored with the G-Rex Grant.

This grant is aimed at supporting his innovative TCR-T cell therapy program, which focuses on new TCR therapies targeting public neoantigens to address high unmet medical needs.

Andrew Scheffler shared a post on Linkedin:

“We are honored to award Memorial Sloan Kettering Cancer Center’s Christopher Klebanoff, and Smita Chandran a G-Rex Grant to support their amazing TCR-T cell therapy program!

Dr. Klebanoff is a member of the Parker Institute for Cancer Immunotherapy and a co-founder of Affini-T Therapeutics.

Dr. Chandran is the Scientific Lead and the discoverer of their novel HLA-A*11/RAS(G12D) TCR-T therapeutic.

Anyone interested in expediting their clinical development and defraying the time and cost associated with generating clinically significant data that your stakeholder expect to see can apply for a G-Rex Grant.”

Christopher Klebanoff replied, saying:

“We are delighted to partner with Scale Ready to help bring innovative new TCR therapies targeting public neoantigens to patients with high unmet medical need! Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy.”